No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

1/7

Sanofi

Alloy

Therapeutics

AntiClastic

Antisense platform

n/d

to develop therapies capable of

crossing the blood-brain barrier

CNS

Unspecified

Discovery

427.5

2

1/10

Eli Lilly

Mediar Therapeutics

MTX-463

WISP1 antibody

Musculoskeletal

Disorders,

Respiratory

Idiopathic Pulmonary

Fibrosis, Fibrosis

Phase 1

786

*3

1/13

AbbVie

Simcere

Pharmaceutical

SIM0500

GPRC5DxBCMAxCD3

tri-specific antibodies

Oncology

Multiple myeloma

Phase 1

1,050

4

1/21

Arrivent

Biopharma

Lepu Biopharma

MRG-007 (ADC)

n/d

Oncology

Gastrointestinal Tract

Cancer,

Colorectal Cancer,

Pancreatic Cancer,

Solid Tumor

Preclinical

1,207

5

1/23

AbbVie

Neomorph

Molecular Glue

n/d

Immunology, Oncology

Unspecified

Immunological Disorders,

Unspecified Cancer

Discovery

1,640

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

1/11

Gilead

Leo Pharma

Oral STAT6 Program, Including Targeted

Protein Degraders

STAT6 Inhibitor

Immunology

Multiple Inflammatory Diseases

Preclinical

1,700

*2

1/13

J&J

Intra-Cellular Therapies

Caplyta

ITI-1284

Lenrispodun

ITI-333

5-HT2A receptor antagonist

5-HT2A receptor antagonist

PDE-1 inhibitor

μ-opioid receptor agonist;
 5-HT2A receptor antagonist

Neurology

Schizophrenia, Bipolar disorder

Alzheimer’s disease, Anxiety

Parkinson's disease

Opioid related disorders

Marketed

Phase 2

Phase 2

Phase 1

3,000

*3

1/13

Eli Lilly

Scorpion Therapeutics

STX-478

PI3Kα inhibitor

Oncology

Breast cancer,

advanced solid tumor

Phase 1/2

2,500

*4

1/13

GSK

IDRx

IDRX-42

RTK inhibitor

Oncology

KIT mutated GIST

Phase 1/2b

1,150

*5

1/13

Lantheus

Life Molecular Imaging

Neuraceq; Florbetaben

β-amyloid radioactive tracer

Neurology

Diagnosis of Alzheimer’s disease

Marketed

750

6

1/28

Lantheus

Evergreen Theragnostics

OCTEVY™(Diagnostic)

EVG-321

PET diagnostic agent

CCK-2R binding and

delivers Lutetium-177

Oncology

Neuroendocrine tumors

Small Cell Lung Cancer,

Unspecified Cancer

Registration

Discovery

1,002